TMS - Page 1 | CARLAT PUBLISHING

Expert Q&A

ECT: An Update

February 1, 2025

W. Vaughn McCall, MD, MS

Professor Emeritus, Department of Psychiatry and Health Behavior; Medical College of Georgia, Augusta University.

Dr. McCall reports that he is a consultant for Alza TV, Axon Medical Technologies, Carelon, Haleon, and Idorsia. Dr. Aiken has reviewed this educational activity and has determined that there is no commercial bias as a result of this financial relationship.

The FDA has changed the labeling on ECT, and Vaughn McCall clarifies where this treatment fits among newer interventions like ketamine and TMS.

Top 10 Findings of Past Year: Treatment Resistant Depression and Benzos

October 14, 2024

Chris Aiken, MD and Kellie Newsome, PMHNP

We count down the top 10 research updates of the past year with a focus on treatment resistant depression and benzo withdrawal.

Research Update

Negative Symptoms of Schizophrenia: A New Target for TMS?

October 1, 2024

Briana Tillman, MD

Briana Tillman, MD. Dr. Tillman has no financial relationships with companies related to this material.

The negative symptoms of schizophrenia are notoriously difficult to address with traditional treatments. The meta-analysis suggests TMS can significantly improve negative symptoms and may offer a promising new treatment approach.

EXPERT Q&A

Understanding TMS: A Primer for Therapists

February 26, 2024

Faizi Ahmed MD

Faizi Ahmed MD. Affiliate Assistant Professor of Psychiatry and Behavioral Neurosciences at the University of South Florida; private practice at The Neuropsychiatry and TMS Group, Tampa, Florida.

Dr. Ahmed has no financial relationships with companies related to this material.

The relevance of transcranial magnetic stimulation for therapists - what they should know about its mechanism, clinical applications, and emerging research.

Expert Q&A

Pharmacological Treatment of Bipolar Disorder in Older Adults

January 31, 2023

John Beyer, MD

John Beyer, MD. Professor of psychiatry, Duke University Medical Center. Durham, NC. Dr. Beyer has consulted for Express Scripts. Relevant financial relationships listed for the author have been mitigated.

With numerous treatment options available for bipolar depression and mania, clinicians often struggle to navigate between medication classes in balancing side effects, efficacy, and costs. Dr. Beyer shares his expertise in choosing first-, second-, third-, and fourth-line options based on their evidence in older adults.